STAINES-UPON-THAMES, United Kingdom, Dec. 16, 2019 /PRNewswire/ — Mallinckrodt plc (NYSE: MNK), a global biopharmaceutical company, today confirmed enrollment of the first patient in the company’s Phase 4, multi-center, multiple-dose, open-label study to...
— Study Primary Endpoint Was Not Met; Improvement in Multiple Measures of Fibrosis and Liver Injury Was Observed with Investigational Firsocostat and Cilofexor — — Regimens Were Well Tolerated and Safety Measures Were Consistent with Prior Studies –...
First allogeneic, off-the-shelf cell therapy approach that enhances T-cell activation through localized OX40-mediated co-stimulation of dormant immune signals DURHAM, NC / ACCESSWIRE / December 16, 2019 / Heat Biologics, Inc. (HTBX), a clinical-stage biopharmaceutical...
– Primary Endpoint of Statistical Superiority Related to Deep Response (VGPR or Better) Was Not Met; However, Zanubrutinib Demonstrated More Frequent VGPRs (28.4% vs.19.2% in Overall Population) – Zanubrutinib Demonstrated Advantages in Safety and...
Puma Biotechnology, Inc. (Nasdaq: PBYI), a biopharmaceutical company, will present updated interim results from a Phase II clinical trial of Puma’s drug neratinib at the 2019 San Antonio Breast Cancer Symposium (SABCS) that is currently taking place in San Antonio,...
Published: Dec 16, 2019 Demonstrated rapid, durable, and statistically significant improvement in depressive symptoms as measured by MADRS total score compared to placebo (p=0.002 on primary endpoint) Statistically significant improvement at week 1 in MADRS total...
Email
Text